Gilead Partners with Yuhan for $81M HIV Drug Ingredient Supply Deal

Partnership Details:
Gilead Sciences has entered into an $81 million deal with South Korea's Yuhan to supply active pharmaceutical ingredients (APIs) for HIV drugs.

Deal Terms:
The agreement gives Gilead access to small molecules against two undisclosed targets in all countries outside of Korea.

Supply Agreement:
This partnership is aimed at enhancing the production of HIV medications by leveraging Yuhan's manufacturing capabilities.

Global Impact:
The deal is expected to contribute to the global supply of HIV drugs, supporting efforts to combat the disease.

Recent Developments:
Gilead has also made significant strides in HIV prevention, with its twice-yearly injectable lenacapavir reducing the risk of HIV infections by 96% in clinical trials.